CD8A and cancer: The efficacy of CpG in cancer immunotherapy is dependent on cross-talk between pDC and conventional DC (mcDC and CD8α DC), the first serving as a source of IFN-I through TLR9 triggering and the latter responding to IFN-I to promote CD8+ T-cell cross-priming and anti-tumor response in melanoma-bearing mice exposed to cryoablation (53).